72 completed, 15 unknown, 10 terminated, 5 withdrawn. 30 Phase 4, 25 Phase 1, 21 Phase 3, 18 Phase 2, 12 Not applicable.
Follow Glyburide: new trials by email Literature Review of Glyburide trials Research Report on Glyburide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis glibenclamide, Placebo - Multiple Sclerosis, Neuropathic Pain | Phase 1 | Not yet recruiting | University of Maryland, Baltimore | 10 | 2026-09-01 | 2025-10-28 |
| Comparison of Metformin Versus Glyburide for Blood Sugar Control in Women With Gestational Diabetes Metformin, Glyburide - Gestational Diabetes Mellitus (GDM) | Phase 4 | Recruiting | Nishtar Medical University | 92 | 2026-04-18 | 2026-09-03 |
| Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Metformin, Cellulose - Sarcoidosis, Pulmonary | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2025-12-10 | 2025-02-11 | |
| Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes MetFORMIN 500 Mg Oral Tablet, GlyBURIDE 2.5 MG Oral Tablet - Gestational Diabetes Mellitus in Pregnancy | Not applicable | Unknown | Assiut University | 180 | 2025-01-01 | 2024-09-19 |
| Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients Voglibose + Metformin, Glibenclamide + Metformin - Diabetes Mellitus Type 2 Without Complication | Phase 3 | Unknown | University of Zambia | 118 | 2023-08-01 | 2023-07-03 |
| Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) Glibenclamide, Pharmacokinetics study, C-peptide proinsulin ratio - Transient; Hypoglycemia, Neonatal, Preterm | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 35 | 2023-05-20 | 2026-10-02 |
| Spinal Cord Injury Neuroprotection With Glyburide GlyBURIDE Oral Tablet - Acute Spinal Cord Injury | Phase 1 | Recruiting | Francis Farhadi | 12 | 2022-07-07 | 2026-02-13 |
| To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI glibenclamide - Traumatic Brain Injury | Phase 1 / Phase 2 | Unknown | Beijing Tiantan Hospital | 76 | 2021-10-22 | 2021-12-08 |
| Evaluate the Use of Glibenclamide on Acute aSAH glibenclamide - Subarachnoid Hemorrhage | Phase 4 | Unknown | Beijing Tiantan Hospital | 110 | 2021-10-19 | 2022-02-14 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 | |
| A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects DBPR108 tablets, Metformin hydrochloride tablets, Glibenclamide tablets - Healthy Subjects | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 56 | 2021-05-26 | 2021-07-20 |
| The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers glibenclamide, PACAP38 - Migraine, Headache | Not applicable | Completed | Danish Headache Center | 22 | 2020-10-20 | 2021-07-14 |
| The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers glibenclamide, CGRP infusion, Placebo - Hemodynamics of Cranial Arteries, Headache | Not applicable | Completed | Danish Headache Center | 20 | 2020-01-20 | 2020-09-09 |
| A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion BIIB093, Placebo - Brain Contusion | Phase 2 | Terminated | Remedy Pharmaceuticals, Inc. | 92 | 2019-10-06 | 2024-11-27 |
| Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers Microgestin®, Levothyroxine, Glyburide - Healthy Volunteers | Phase 1 | Completed | Ironwood Pharmaceuticals, Inc. | 87 | 2019-03-11 | 2019-07-29 |
| Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) Sulfonylurea - Permanent Neonatal Diabetes Mellitus | Phase 4 | Unknown | Haukeland University Hospital | 30 | 2019-02-15 | 2020-02-12 |
| Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage Glibenclamide Tablets, Standard management for ICH - Intracerebral Hemorrhage | Not applicable | Completed | Xijing Hospital | 220 | 2018-12-15 | 2022-04-08 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction BIIB093, Placebo - Brain Edema, Stroke, Acute | Phase 3 | Terminated | Remedy Pharmaceuticals, Inc. | 535 | 2018-08-29 | 2024-11-25 |
| Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage Glibenclamide, Placebo - Subarachnoid Hemorrhage, Aneurysmal | Phase 4 | Unknown | University of Sao Paulo General Hospital | 50 | 2018-07-03 | 2018-06-26 |
| A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. ) Glibesyn, Daonil - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 27 | 2018-06-30 | 2019-02-26 |
Showing 20 of 106. Sign in to see all of them.
Diabetes Mellitus, Type 2 (41) · Diabetes Mellitus (28) · Diabetes, Gestational (14) · Dyslipidemias (6) · Glucose Metabolism Disorders (6) · Hypoglycemia (6) · Insulin Resistance (5) · Diabetes Mellitus, Lipoatrophic (4) · Diabetes Mellitus, Type 1 (4) · Brain Edema (3) · Brain Injuries, Traumatic (3) · Hypertension (3) · Ischemic Stroke (3) · Stroke (3) · Diabetes Mellitus, Permanent Neonatal (2)
Takeda (6) · Remedy Pharmaceuticals, Inc. (5) · Assistance Publique - Hôpitaux de Paris (4) · Novo Nordisk A/S (4) · Actavis Inc. (3) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Haukeland University Hospital (3) · Hospital de Clinicas de Porto Alegre (3) · AstraZeneca (2) · Beijing Tiantan Hospital (2) · Bristol-Myers Squibb (2) · Danish Headache Center (2) · Sanofi (2) · Teva Pharmaceuticals USA (2) · University of Campinas, Brazil (2)
United States (38) · Brazil (11) · Canada (10) · China (8) · Italy (8) · France (7) · United Kingdom (7) · Israel (6) · Germany (5) · Norway (5) · Australia (4) · Denmark (4) · Japan (4) · Mexico (4) · Spain (4)
Pierre Ernst, MD, MSc (3) · James D. Carlson,, Pharm.D, (2) · Lisa E Moore, MD (2) · Michel Polak, MD, PhD (2) · Ahmed Elshafeey, Ph.D. Pharma (1) · Alan J Bank, M.D. (1) · Aline AF Fofonka, MSc (1) · B. Bravenboer, MD, PhD (1) · Beatriz BS Schaan, PhD (1) · Bruno Jolain (1)
PMID 20027034, PMID 32501595, PMID 11372010, PMID 12351470, PMID 15115830, PMID 15448106, PMID 15561950, PMID 15611492, PMID 16873701, PMID 16885549, PMID 16885550, PMID 17116177, PMID 17145742, PMID 17362692, PMID 18025408, PMID 18223031, PMID 18672190, PMID 19125778, PMID 19394661, PMID 19592630, PMID 19670918, PMID 19793357, PMID 19808911, PMID 20199137, PMID 20557330, PMID 21209033, PMID 21454723, PMID 21562067, PMID 21680990, PMID 22078152, PMID 22723578, PMID 23010561, PMID 23051145, PMID 23273975, PMID 23286943, PMID 23795975, PMID 24023652, PMID 24193798, PMID 24843595, PMID 24932223, PMID 25366037, PMID 26241419, PMID 26281972, PMID 26312070, PMID 26438614, PMID 26888382, PMID 27007958, PMID 27033025, PMID 27140803, PMID 27402391
2005 (1), 2014 (1), 2015 (1), 2017 (1), 2018 (1), K23HD092893 (1), R01DK103841 (1)